Kane Biotech Inc KNBIF

Buzz on the Bullboards: Stocks to watch in volatile times.

[francoisl13]

Correct and if I understand well, this upcoming collaboration will, again, be for DispersinB. He also made a comment, and this is not the first time he does, about the fact that other major players in

[KevinOleary]

He also said there could be another multinational collaboration, which would be in addition to the one he announced in the last month or so.

[francoisl13]

Well... 3rd QTR numbers are out and they look pretty decent to me especially on the expenses front. If you take into account everything that happened during the past QTR, it is pretty amazing to see

[lscfa]

During the 3rd quarter, the Company recorded $594,705 from its 1st commercial sales of revyveTM Antimicrobial Wound Gel to its US distributor ProgenaCare.

[KevinOleary]

Why don't you send them a few hundred thousand so they can get on with your project? Every board has someone like you, with no work experience in the market pumping field where you think you'

[MirrorWorldMan]

I think they can do much more; omnichannel marketing to reach more investors, hosting fund managers, linking into patient support networks etc

[KevinOleary]

mwm Are you not able to understand the frequent videos? If so maybe investing isn't for you, because there is only so much that a company with all these novel products can explain. The investor of

[MirrorWorldMan]

I believe everyone benefits from proficient investor relations.  Relaying channeled enthusiasm to the right group of new investors in simplified terms sets a BT apart from the regular science

[PressRelease]

Company Records First Commercial Sale of revyve™ Wound Gel WINNIPEG, Manitoba, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announces its third quarter 2024 financial results.Third Quarter 2024 Financial Highlights ...read article.

[KevinOleary]

lol MWM, at this point the quarterly cc is all the update anyone needs along with the presentation. It's not that complicated really, and the products are just being rolled out so no one even at

[KevinOleary]

Every sale after Nov 20th goes to BSEM's account when they close in January, so they put the product on the VM site to drive any VM customers who see Revyve now straight to Progena. Then in

[Jonathon Brown]

The TSX hit another record high on strong retail sales data and positive investor sentiment. However, the index quickly fell from grace. read article.

[francoisl13]

Can't disagree with you MWM. Mark and his team at Kane did a wonderful job in the past 18-24 months but it might be time to hire someone to do the link with the investment community and have a

[francoisl13]

I know KOleary...I was surprised to see Progenacare and Kane products already listed/promoted on Venture Medical website therefore asking the question...Were they already involved with Progenacare

[MirrorWorldMan]

It is my feeling that there has been a plethora of recent announcements and Marc would do well by calling consolidating and encapsulating  them all to the average potential shareholder in simple

[KevinOleary]

Venture M markets Biostem's products for them. Biostem is not a marketer.